Information  X 
Enter a valid email address

BioPharma Credit PLC (BPCR)

  Print   

Wednesday 09 September, 2020

BioPharma Credit PLC

LEXICON PHARMACEUTICALS PREPAYMENT

RNS Number : 5195Y
BioPharma Credit PLC
09 September 2020
 

9 september 2020

 

BioPharma Credit plc

(the "Company")

 

LEXICON Pharmaceuticals PREPAYMENT

   

Pharmakon Advisors, the Investment Manager of BioPharma Credit PLC (the "Company"), notes that Lexicon Pharmaceuticals ("Lexicon") has repaid in full its $150 million secured term loan, of which the Company owned $124.5 million.  As a result of the repayment, the Company received $132.3 million today from Lexicon, comprised of $124.5 million in principal, $2.2 million in accrued interest and $5.6 million in make-whole amount and prepayment fees. This investment generated an IRR of 12.1%.

Enquiries

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0)1392 477 500

 

Buchanan

+44 (0)20 7466 5000 / [email protected]

David Rydell

Mark Court

Jamie Hooper

Henry Wilson

 

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27   March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

 

LEI: 213800AV55PYXAS7SY24

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFLFEVATIAIII

a d v e r t i s e m e n t